Dose-attenuated IST and Hetrombopag in Elderly (65 Years) Patients With Severe Aplastic Anemia
Status:
RECRUITING
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (65 years) with VSAA/SAA.
Phase:
PHASE2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China